文献速递慢性肾脏病血液净化与透析

评估肾小球滤过率斜率作为临床试验终末期肾病替代终点的个体参与者荟萃分析

Evaluating Glomerular Filtration Rate Slope as a Surrogate End Point for ESKD in Clinical Trials: An Individual Participant Meta-Analysis of Observational Data.
PubMed 文献 · J Am Soc Nephrol · 2019-07-10

该研究基于14个队列的个体参与者数据,分析eGFR下降斜率与长期ESKD风险的关联。结果显示,eGFR下降较慢与ESKD风险降低相关,即使在基线eGFR≥60 ml/min per 1.73 m2的人群中亦然,且高风险人群获益更大。

要点

  • 2年内eGFR下降减缓0.75 ml/min per 1.73 m2/年与ESKD风险降低相关。
  • 基线eGFR≥60 ml/min per 1.73 m2者调整HR为0.70(95%CI 0.68-0.72)。
  • 高风险人群(5年ESKD风险8.3%)绝对风险降低1.6%,低风险人群仅0.13%。

核心结论

  • eGFR下降较慢与后续ESKD风险降低相关,即使在eGFR≥60 ml/min per 1.73 m2的参与者中也是如此。
  • ESKD风险最高的人群预期从减缓eGFR下降的干预中获益最大。

研究设计与样本

  • 对14个队列的个体参与者数据进行随机效应荟萃分析,平均随访4.2年。
  • 包含基线eGFR≥60 ml/min per 1.73 m2的参与者3,758,551例和eGFR<60 ml/min per 1.73 m2的参与者122,664例。

主要发现

  • 2年内eGFR下降减缓0.75 ml/min per 1.73 m2/年与ESKD风险降低相关:基线eGFR≥60者调整HR 0.70(95%CI 0.68-0.72),eGFR<60者HR 0.71(95%CI 0.68-0.74)。
  • 3年斜率与结局的关系更强。
  • 预测5年ESKD风险8.3%的快速进展人群,相同干预可降低ESKD风险1.6%;预测5年ESKD风险0.58%的低风险人群仅降低0.13%。

临床怎么用

  • 在临床试验中,eGFR斜率可作为ESKD的替代终点,但需考虑人群基线风险。
  • 高风险人群更可能从减缓eGFR下降的干预中获益,试验设计应优先纳入。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Decline in eGFR is a biologically plausible surrogate end point for the progression of CKD in clinical trials. However, it must first be tested to ensure strong associations with clinical outcomes in diverse populations, including patients with higher eGFR. METHODS: To investigate the association between 1-, 2-, and 3-year changes in eGFR (slope) with clinical outcomes over the long term, we conducted a random effects meta-analysis of 3,758,551 participants with baseline eGFR≥60 ml/min per 1.73 m2 and 122,664 participants with eGFR<60 ml/min per 1.73 m2 from 14 cohorts followed for an average of 4.2 years. RESULTS: Slower eGFR decline by 0.75 ml/min per 1.73 m2 per year over 2 years was associated with lower risk of ESKD in participants with baseline eGFR≥60 ml/min per 1.73 m2 (adjusted hazard ratio, 0.70; 95% CI, 0.68 to 0.72) and eGFR<60 ml/min per 1.73 m2 (0.71; 95% CI, 0.68 to 0.74). The relationship was stronger with 3-year slope. For a rapidly progressing population with predicted 5-year risk of ESKD of 8.3%, an intervention that reduced eGFR decline by 0.75 ml/min per 1.73 m2 per year over 2 years would reduce the ESKD risk by 1.6%. For a hypothetical low-risk population with a predicted 5-year ESKD risk of 0.58%, the same intervention would reduce the risk by only 0.13%. CONCLUSIONS: Slower decline in eGFR was associated with lower risk of subsequent ESKD, even in participants with eGFR≥60 ml/min per 1.73 m2, but those with the highest risk would be expected to benefit the most.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Grams ME, Sang Y, Ballew SH, et al. Evaluating Glomerular Filtration Rate Slope as a Surrogate End Point for ESKD in Clinical Trials: An Individual Participant Meta-Analysis of Observational Data. J Am Soc Nephrol. 2019. PMID: 31292199. doi:10.1681/ASN.2019010008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。